View Press Releases
-
Monon Bioventures receives nearly $400,000 to develop Purdue-discovered glioblastoma treatment
Monon Bioventure receives funding to develop Purdue-discovered glioblastoma treatment
Sep 27, 2022
-
Samsung Biologics Earns Gold Rating from EcoVadis for Its Sustainability Efforts
-
Alfa Chemistry Offers Abundant Choices of Alternative Energy Materials for Energy Storage & Batteries
-
Quanticate partners with Cancer Research UK to launch DETERMINE Study
-
Vyasa Adds Real-Time Dashboards to Layar Data Fabric
Vyasa, an innovative provider of highly scalable deep learning A.I. analytics software for healthcare, life sciences and business applications, today introduces its latest application interface, Signal. Featuring an intuitive design, Signal enables users to monitor trends and identify anomalies in their Layar data fabric through highly-visual charts and graphs delivered in a single dashboard.
Sep 26, 2022
-
Bora Pharmaceuticals partners with TaiRx, Inc. to manufacture breakthrough anticancer drug
-
Integrated DNA Technologies Launches New PrimeTime™ qPCR One-Step Master Mix with Exclusive Mutant Enzyme
-
BioIVT Acquires Fidelis Research
This transaction increases BioIVT's global network for collecting high-quality, disease-state biospecimens and extends its capabilities to deliver fresh biospecimens and produce cell products for drug and diagnostic development.
Sep 25, 2022
-
Abzena strengthens R&D capabilities to support rapid antibody discovery
For further information, images, and interview opportunities, please contact Kristy Harmer at ramarketing: kristy.harmer@ramarketingpr.com | +44 (0)191 222 1242 | ramarketingpr.com | Twitter: @ramarketingpr | Facebook: /ramarketingpr | Linkedin: /ramarketing About Abzena Abzena provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and bioconjugation drug development and manufacturing in the biopharmaceutical industry. The company maintains resources around the world, with facilities in the US and UK. Abzena is owned by Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors. For more information, please see www.abzena.com.
Sep 22, 2022
-
Zebrafish Disease Models: Accelerating Human Disease Studies and Biomedical Research
-
Microbiosci Offers Real-time PCR Kits to Support Research Applications in Viral Detection
-
CRISPR/Cas9 Platform Provides Accurate Gene Knockout Mouse Models for Immunology Research and Drug Discovery
-
DDA Platform Offers A Wide Range of in Vitro and in Vivo Assays to Cover Early Stage Drug Discovery
-
Creative Bioarray Provides Cell Patterning Customization and Detection Services for Drug Screening
-
Creative Bioarray Designs Comprehensive Tools and Protocols to Construct Animal Disease Models
-
Creative Enzymes Offers Products to Support the Clinical and Research Use of Liver Function Evaluation
-
Creative Enzymes Announces the Launch of Kex2 Protease from Saccharomyces Cerevisiae, Recombinant
-
Scitara announces partnership with Agilent to benefit customers with enhanced digital lab connectivity
-
Debut Event Showcases Newest Trends in Drug Manufacturing and Delivery
Connect in Pharma provided a platform where key players in European pharma found innovative, patient-centric and sustainable solutions for strengthening the pharmaceutical supply chain.
Sep 21, 2022
-
Creative Proteomics Cytokine Accelerates Your Project with Its Colony Stimulating Factor Detection Service